Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial

American Heart Journal

Volumn 190, Issue , 2017, Pages 113-122

  Gimpelewicz, Claudio ^a   Metra, Marco ^b   Cleland, John G F ^c,d   Szecsödy, Peter ^a   Chang Wun, Chuan Chuan ^a   Boer Martins, Leandro ^a   Cotter, Gad ^e   Davison, Beth A ^e   Felker, Gary Michael ^f   Filippatos, Gerasimos ^g   Greenberg, Barry H ^h   Pang, Peter ⁱ   Ponikowski, Piotr ^j   Severin, Thomas ^a   Voors, Adrian A ^k   Teerlink, John R ^l  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e Momentum Research Inc   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j WROCLAW MEDICAL UNIVERSITY   (Poland)

^k UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOOP DIURETIC AGENT; NITRIC ACID DERIVATIVE; PLACEBO; SERELAXIN; RECOMBINANT PROTEIN; RELAXIN; SERELAXIN PROTEIN, HUMAN;

ACUTE HEART FAILURE; AGED; ARTICLE; CENTRAL VENOUS PRESSURE; DRUG RESPONSE; DYSPNEA; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LUNG CONGESTION; MAJOR CLINICAL STUDY; MALE; MODERATE RENAL IMPAIRMENT; MULTICENTER STUDY (TOPIC); PERIPHERAL EDEMA; POST HOC ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; ACUTE DISEASE; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DOSE RESPONSE; EDEMA; HEART FAILURE; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ACUTE DISEASE; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; FEMALE; HEART FAILURE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; RECOMBINANT PROTEINS; RELAXIN; TREATMENT OUTCOME;

EID: 85020866884     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2017.05.012     Document Type: Article

References (25)

1. 1. Teerlink, J.R., Cotter, G., Davison, B.A., et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381 (2013), 29–39.
2. 2. Teerlink, J.R., Metra, M., Felker, G.M., et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 373 (2009), 1429–1439.
3. 3. Mentz, R.J., Hernandez, A.F., Stebbins, A., et al. Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. Eur J Heart Fail 15 (2013), 456–464.
4. 4. Konstam, M.A., Gheorghiade, M., Burnett, J.C. Jr., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297 (2007), 1319–1331.
5. 5. Massie, B.M., O'Connor, C.M., Metra, M., et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 363 (2010), 1419–1428.
6. 6. Allen, L.A., Hernandez, A.F., O'Connor, C.M., et al. End points for clinical trials in acute heart failure syndromes. J Am Coll Cardiol 53 (2009), 2248–2258.
7. 7. Gheorghiade, M., Pang, P.S., Acute heart failure syndromes. J Am Coll Cardiol 53 (2009), 557–573.
8. 8. Shoaib, A., Waleed, M., Khan, S., et al. Breathlessness at rest is not the dominant presentation of patients admitted with heart failure. Eur J Heart Fail 16 (2014), 1283–1291.
9. 9. Cotter, G., Felker, G.M., Adams, K.F., et al. The pathophysiology of acute heart failure—is it all about fluid accumulation?. Am Heart J 155 (2008), 9–18.
10. 10. Cotter, G., Metra, M., Milo-Cotter, O., et al. Fluid overload in acute heart failure—re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail 10 (2008), 165–169.
11. 11. Clark, A.L., Almanac 2013: heart failure. Heart 99 (2013), 1562–1566.
12. 12. Ponikowski, P., Mitrovic, V., Ruda, M., et al. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur Heart J 35 (2014), 431–441.
13. 13. Ponikowski, P., Metra, M., Teerlink, J.R., et al. Design of the RELAXin in acute heart failure study. Am Heart J 163 (2012), 149–155 [e1].
14. 14. Shoaib, A., John, J., Gupta, S., et al. Characteristics and outcome of patients admitted to hospital with heart failure according to the severity of peripheral oedema in the national (England & Wales) heart failure audit. Eur Heart J, 36, 2015 [Abstract Supplement, 1177 2015;36].
15. 15. Clark, A.L., Cleland, J.G., Causes and treatment of oedema in patients with heart failure. Nat Rev Cardiol 10 (2013), 156–170.
16. 16. Gheorghiade, M., De Luca, L., Fonarow, G.C., et al. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol 96 (2005), 11G–17G.
17. 17. Damy, T., Kallvikbacka-Bennett, A., Goode, K., et al. Prevalence of, associations with, and prognostic value of tricuspid annular plane systolic excursion (TAPSE) among out-patients referred for the evaluation of heart failure. J Card Fail 18 (2012), 216–225.
18. 18. Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18 (2016), 891–975.
19. 19. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 2016.
20. 20. Voors, A.A., Davison, B.A., Teerlink, J.R., et al. Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome—an analysis from RELAX-AHF. Eur J Heart Fail 16 (2014), 1230–1240.
21. 21. Butler, J., Gheorghiade, M., Kelkar, A., et al. In-hospital worsening heart failure. Eur J Heart Fail 17 (2015), 1104–1113.
22. 22. Jelinic, M., Leo, C.H., Post Uiterweer, E.D., et al. Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment. FASEB J 28 (2014), 275–287.
23. 23. Sarwar, M., Du, X.J., Dschietzig, T.B., et al. The actions of relaxin on the human cardiovascular system. Br J Pharmacol, 2016, 10.1111/bph.13523.
24. 24. Snowdown, V.K., Lachlan, N.J., Hoy, A.M., et al. Serelaxin as potential treatment for renal dysfunction in cirrohosis: preclinical evaluation and results of a randomize phase 2 trial. PLoS Med, 14, 2017, e1002248.
25. 25. Metra, M., Cotter, G., Davison, B.A., et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 15 (2013), 196–206.